Physician profile
Theodore Burden
NPI 1811980030
$7,432.00
in general payments reported to CMS, 2019-2025
38 companies · $906 in 2025
The $906 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $784 · 2021: $1,808 · 2022: $1,697 · 2023: $1,526 · 2024: $458 · 2025: $906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,889.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,889.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,425.81 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $741.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $710.45 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $638.28 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $384.19 | 2020-2024 | Synjardy, Jardiance, Tradjenta |
| Teva Pharmaceuticals USA, INC. | $303.49 | 2022-2025 | Austedo, Austedo Xr, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $300.89 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $291.51 | 2021-2025 | |
| Pfizer INC. | $246.26 | 2020-2025 | |
| Medtronic, INC. | $232.70 | 2022-2023 | Minimed 780g, Minimed 770g, Inpen Smart Insulin Delivery System |
| Biohaven Pharmaceuticals, INC. | $222.47 | 2021 | |
| Lilly USA, LLC | $219.15 | 2020-2025 | Mounjaro, Amyvid, Zepbound |
| Exact Sciences Corporation | $207.90 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $158.85 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $147.60 | 2021-2023 | Belsomra |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Burden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.